ArticlePediatric nephrology (Berlin, Germany)2026
Using a multi-institutional pediatric learning health system to characterize induction therapy for incident lupus nephritis in children.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is It Time to Change Our Approach to Childhood Lupus Nephritis?Journal of the American Society of Nephrology : JASN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundChildhood-onset systemic lupus erythematosus (SLE) poses unique challenges compared to adult-onset SLE, with higher rates of kidney involvement, tissue damage, and mortality. Despite this, data on the effectiveness of immunomodulatory therapies, particularly for lupus nephritis (LN), in pediatric populations are limited. We leveraged a U.S. national learning health system to describe induction treatment in children with LN.
methodsA previously validated LN case-finding algorithm was used to identify patients. Index date was the date of the first LN diagnosis code or the date of the first kidney biopsy, whichever came first. Induction medications included corticosteroids (IV and PO), cytotoxic agents (cyclophosphamide, IV), antimetabolites (mycophenolate mofetil, mycophenolic acid) and biologics (rituximab, belimumab).
results575 children with LN were identified. Median age at entry was 15.1 years, 78.6% had evidence of a kidney biopsy, and 56.3% of patients received at least one non-corticosteroid immunosuppressive medication within 6 months of the index date. Prescribed or administered agents during the induction period were: corticosteroids (85%), antimetabolite (61.6%), biologic agent (13.7%), cytotoxic agent (21%). Among the 15% not prescribed or administered corticosteroids, but prescribed or administered an additional immunosuppressive medication, 100% were prescribed or administered antimetabolites. The most common first non-corticosteroid agents were antimetabolites (61.6%), cytotoxic agents (21%) and biologics (13.7%), while biologics were the most common second-line agent.
conclusionsWe utilized a validated, sensitive and specific computable phenotype to identify children and adolescents with LN and subsequently characterize their induction therapy regimens, a critical first step in designing future pragmatic clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.